These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Drug importation and safety of drugs obtained from Canada. Shepherd M Ann Pharmacother; 2007 Jul; 41(7):1288-91. PubMed ID: 17578879 [TBL] [Abstract][Full Text] [Related]
26. [Scope of the contract for drug therapy. Rebate contracts also for original drugs]. MMW Fortschr Med; 2009 Jul; 151(30-33):80. PubMed ID: 19722473 [No Abstract] [Full Text] [Related]
27. WHO must defend patients' interests, not industry. Cawthorne P; Ford N; Limpananont J; Tienudom N; Purahong W Lancet; 2007 Mar; 369(9566):974-5. PubMed ID: 17382809 [No Abstract] [Full Text] [Related]
28. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Fischer MA; Avorn J Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087 [TBL] [Abstract][Full Text] [Related]
30. [For the first time a health insurance company publishes drug data. Surprise: the thriftiest colleagues are in the East]. Schmidt K MMW Fortschr Med; 2001 Nov; 143(44):53. PubMed ID: 11732399 [No Abstract] [Full Text] [Related]
31. Statin utilisation--recognising the role of the invisible hand. Minhas R Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171 [No Abstract] [Full Text] [Related]
32. [Prescription of generic preparations]. Ingerslev N Ugeskr Laeger; 1993 Jan; 155(4):253-4. PubMed ID: 8430476 [No Abstract] [Full Text] [Related]
33. [Discount for only one drug of the same group leads to impaired health care quality]. Bergström R Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044 [No Abstract] [Full Text] [Related]
34. Pharmaceutical supply chain in China: current issues and implications for health system reform. Yu X; Li C; Shi Y; Yu M Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912 [TBL] [Abstract][Full Text] [Related]
35. [Cheap drugs with expensive health consequences]. Milerad J Lakartidningen; 2008 Jan 30-Feb 5; 105(5):264. PubMed ID: 18368952 [No Abstract] [Full Text] [Related]
37. Pricing of drugs with heterogeneous health insurance coverage. Ferrara I; Missios P J Health Econ; 2012 Mar; 31(2):440-56. PubMed ID: 22484368 [TBL] [Abstract][Full Text] [Related]
38. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness]. Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404 [TBL] [Abstract][Full Text] [Related]
39. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]